Medivation, Inc. (MDVN) reported a net loss for the first quarter of $27.2 million or $0.36 per share, compared to net income of $0.4 million or $0.01 per share for the year-ago quarter. The net income in the first quarter of 2012 resulted from the acceleration of unamortized revenue from the Company's former collaboration with Pfizer.
Collaboration revenue for the latest first quarter rose to $46.15 million from $36.83 million a year ago.
Analysts polled by Thomson Reuters expected the company to report a loss of $0.41 per share on revenue of $38.54 million for the first quarter.
XTANDI net sales for the first quarter of 2013, as reported by Astellas, were $75.4 million, which included a favorable gross-to-net adjustment of $4.4 million taken by Astellas relating to prior quarters.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.